|
10th Anniversary Conference Of The British HIV Association [BHIVA]15 – 17 April 2004, City Hall, Cardiff, UK |
[AUTHOR(S):] R Jones, J Stebbing, MR Nelson, G Moyle, M Bower, S Mandalia, BG Gazzard
Chelsea and Westminster Hospital, London, UK
BHIVA Conf 2004 Apr 15-17;10:P3
BACKGROUND: Despite recent case reports, there are no data on the overall incidence and risk of renal dysfunction in individuals receiving TDF.
METHODS: Data from the Chelsea and Westminster cohort were analysed to identify HIV-positive individuals with creatinine >120 µmol/l at any time and to classify them according to HAART exposure and time exposed. A matched case–control study was performed, comprising patients who had received TDF and subsequently developed creatinine >120 µmol/l, against controls who had been treated with TDF and not experienced creatinine elevation.
RESULTS: From 4183 HIV-infected patients, 1175 were identified as having a recorded creatinine >120 µmol/l. Comparison of HAART-naïve patients, and patients exposed to TDF and non-TDF containing regimes revealed a lower rate ratio and probability of developing creatinine >120 µmol/l in patients exposed to TDF (rate ratio versus no antiretrovirals 0.22, 95% confidence interval 0.07–0.69, P<0.001) with no significant difference between HAART regimens, corrected for duration of exposure. Of the 1058 patients exposed to TDF, 84 (8%) experienced creatinine >120 µmol/l subsequent to exposure. An alternative aetiology for renal dysfunction was found in 75 (90%) individuals.
CONCLUSIONS: TDF is not associated with renal dysfunction more frequently than other antiretrovirals and the occurrence of renal dysfunction in this context is a rare and idiosyncratic event.
PRESENTING AUTHOR: R Jones
040415
P3
Copyright © 2004 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD